Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3417
Gene Symbol: IDH1
IDH1 		0.100 GeneticVariation disease BEFREE Diffuse astrocytoma (DA), anaplastic astrocytoma (AA), and glioblastoma (GBM) are defined by the World Health Organization (WHO) based on IDH-mutational status. 28110298 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2 		0.050 GeneticVariation disease BEFREE Diffuse astrocytoma (DA), anaplastic astrocytoma (AA), and glioblastoma (GBM) are defined by the World Health Organization (WHO) based on IDH-mutational status. 28110298 2017
Entrez Id: 5978
Gene Symbol: REST
REST 		0.010 AlteredExpression disease BEFREE Means of relative expression for REST were as follows: 0.7898, 0.7606, and 0.7318 in DA, AO, and GBM groups, respectively. 27685921 2017
Entrez Id: 3627
Gene Symbol: CXCL10
CXCL10 		0.010 GeneticVariation disease BEFREE 50.7% of GBM and 24.5% of DA showed strong immunoexpression of CXCL10. 27461653 2017
Entrez Id: 2833
Gene Symbol: CXCR3
CXCR3 		0.010 Biomarker disease BEFREE Strong CXCR3 immunoexpression was observed in 72.7% cases of GBM as compared to 31.8% cases of DA. 27461653 2017
Entrez Id: 23186
Gene Symbol: RCOR1
RCOR1 		0.010 AlteredExpression disease BEFREE For RCOR1, expression means in DA, AO, and GBM groups were 0.7203, 0.7334, and 0.7230, respectively. 27685921 2017
Entrez Id: 488
Gene Symbol: ATP2A2
ATP2A2 		0.010 AlteredExpression disease BEFREE Here, we examined ATP2A2 expression in 109 human diffuse astrocytic tumor samples (39 grade II diffuse astrocytoma (DA), 19 grade III anaplastic astrocytoma (AA), 51 grade IV glioblastoma) and its correlation with patient clinicopathologic characteristics. 28339043 2017
Entrez Id: 6853
Gene Symbol: SYN1
SYN1 		0.010 AlteredExpression disease BEFREE SYN1 expression means were as follows: 0.3936, 0.3192, and 0.3197 in DA, AO, and GBM groups, respectively. 27685921 2017
Entrez Id: 3417
Gene Symbol: IDH1
IDH1 		0.100 GeneticVariation disease BEFREE Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. 29016996 2018
Entrez Id: 3417
Gene Symbol: IDH1
IDH1 		0.100 GeneticVariation disease BEFREE In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second. 29077933 2018
Entrez Id: 3417
Gene Symbol: IDH1
IDH1 		0.100 GeneticVariation disease BEFREE The diagnosis was IDH-mutated diffuse astrocytoma, WHO grade II. 30079885 2019
Entrez Id: 3417
Gene Symbol: IDH1
IDH1 		0.100 GeneticVariation disease BEFREE For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. 30878754 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2 		0.050 GeneticVariation disease BEFREE The diagnosis was IDH-mutated diffuse astrocytoma, WHO grade II. 30079885 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2 		0.050 GeneticVariation disease BEFREE For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. 30878754 2019